1379540-62-1Relevant articles and documents
COMPOUNDS TARGETING PRMT5
-
, (2021/10/11)
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER
-
, (2020/04/25)
KMT9, METTL21A and METTL21B, are characterized herein for the first time as histone methyl transferases involved in the proliferation of cancer cells. Inhibitors of the same can be used for treating cancer. The present invention concerns, inter alia, a selective KMT9- inhibitor for use in the treatment of cancer, in particular prostate cancer.
ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND
-
Paragraph 0445-0447, (2018/11/21)
Disclosed is an antitumor effect potentiator for one or more other compounds having an antitumor effect, the antitumor effect potentiator comprising a novel pyrrolopyrimidine compound.